Zolac

Quick links to important sections

Zolac

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolac

Quick Facts

Property Description
Active Ingredient Bromocriptine Mesilate
Form Oral Tablet
Pharmacological Class Dopamine Agonist, Prolactin Inhibitor
General Purpose Corrects neuroendocrine imbalances
Origin Semisynthetic Ergot Alkaloid Derivative

What Type of Medicine is Zolac and What Is Its Composition?

Zolac is a prescription-only medication supplied as an oral tablet, containing the single active chemical agent, Bromocriptine. The preparation specifically utilizes Bromocriptine Mesilate, a stable salt form that ensures optimal delivery of the active compound for systemic action throughout the body. The active substance is structurally identified as a semisynthetic ergot alkaloid derivative, a chemical designation that distinguishes its origin and pharmacological properties from other drug classes.

This compound provides consistent absorption and targeted effects on the neuroendocrine system. This single active ingredient formulation is intended exclusively for oral intake.


Zolac's Pharmacological Class and Primary Action

Zolac is clinically and functionally defined by its primary classifications as both a Dopamine Agonist and a potent Prolactin Inhibitor. This means the medicine acts by selectively stimulating postsynaptic dopamine receptors, while concurrently blocking the secretion of the hormone prolactin from the anterior pituitary gland.

As a Dopamine Agonist, the substance mimics the body's natural chemical messenger, dopamine, initiating crucial signals necessary for various regulatory processes. The designation as a Prolactin Inhibitor highlights its strong ability to suppress prolactin release for managing conditions linked to hormonal overproduction. This confirms that the medicine works by directly modulating the hormonal system to suppress a specific pituitary output.


General Purpose of Bromocriptine Mesilate

The general purpose of Bromocriptine Mesilate is to normalize processes dependent on adequate dopamine signaling and to correct health issues resulting from neuroendocrine dysregulation. This corrective action focuses on conditions where a functional deficit in the dopamine system or an excess of the hormone prolactin is a primary pathological factor.

A typical use scenario involves stabilizing a hormonal profile where excess prolactin is disrupting normal physiological cycles. The medicine's primary benefit is centered on providing reliable, systemic modulation of these endocrine and neurological pathways, which defines its broad utility in the context of hormonal and neurochemical disorders.

Regulatory References

  1. Bromocriptine: MedlinePlus Drug Information

What side effects are possible with Zolac?

Possible Side Effects and Safety Information

The safety profile for Zolac is established through governmental regulatory documents, which categorize known risks by system-organ class and frequency.

Common Adverse Reactions

The most commonly reported side effects typically affect the Gastrointestinal system and General disorders. These include nausea, vomiting, diarrhea, constipation, and abdominal pain. Many patients experience a temporary flu-like syndrome, including fever, chills, headache, and myalgia (muscle pain), which is most prominent at the start of therapy and usually decreases with continued treatment.

Serious and Clinically Significant Adverse Reactions

Official documents highlight several serious and clinically significant risks associated with the use of Zolac or its drug class. These adverse reactions require attention as they may be life-threatening or result in permanent disability:

  • Cardiovascular: Acute myocardial infarction, stroke, sudden cardiac death, and hypertension have been reported.
  • Vascular/Hematologic: Serious events such as pulmonary embolism, tumour haemorrhage, and thrombocytopenia (low platelet count) are documented.
  • Skeletal/Dental: The risk of osteonecrosis of the jaw (ONJ), a serious condition of the jaw bone, and severe, incapacitating bone, joint, and/or muscle pain are noted in safety warnings.
  • Renal: Deterioration of renal function (kidney damage) has been reported, particularly in patients with pre-existing impairment or inadequate hydration.
  • Ocular: Ocular inflammatory effects, such as uveitis, are an uncommon but documented risk.

Safety Considerations

Certain groups require specific caution as outlined in the official warnings. Patients with pre-existing cardiac conditions or renal impairment may face an increased risk of adverse outcomes. Due to the potential for fetal harm, women of childbearing potential are advised to avoid becoming pregnant while receiving this therapy. Safety monitoring, including the assessment of serum creatinine before each dose, is a standard high-level note in the regulatory text to mitigate the risk of renal toxicity.

Overdose and Emergency Response

Overdose Scope

Element Regulatory Statement
Documented overdose presentations Clinical manifestations may include nausea, vomiting, dizziness, somnolence (drowsiness), confusion, hallucinations, and yawning. Severe outcomes involve profound hypotension (very low blood pressure) and fainting (syncope).
Physiological systems affected Central Nervous System (CNS) and Cardiovascular System.
Dose-related or exposure-related factors Acute ingestions, which have been frequently reported in children, often resulting in vomiting, drowsiness, and hypotension. Overdose is also a consideration in patients with impaired hepatic function due to potentially retarded elimination.
Emergency-response statements Treatment should be symptomatic and supportive. Management of severe hypotension is required.
When immediate medical help is required Regulatory information mandates to seek emergency medical attention immediately upon suspected overdose. Contacting a Poison Help line is also required for immediate guidance.

Overdose Classifications (High-Level)

Element Regulatory Statement
Severity classification The potential for severe hypotension and syncope classifies the overdose as potentially serious, requiring immediate medical intervention.
Overdose-context constraints No specific antidote is known or documented in the official labeling.

Resulting Overdose Structure

Official overdose statements:

  • Overdose is characterized by documented neurological symptoms including confusion, dizziness, somnolence, and hallucinations.
  • The primary acute risk requiring urgent attention is potentially life-threatening profound hypotension (low blood pressure) and subsequent syncope.
  • Regulatory guidance explicitly mandates that individuals seek emergency medical attention immediately upon suspicion of an overdose.

Connection to the overall overdose profile:

The official prescribing information defines the Bromocriptine Mesilate overdose profile by documenting expected neurological signs alongside the critical cardiovascular instability. The presence of severe hypotension and syncope dictates the required action, which is immediate medical attention, and the care strategy, which is strictly symptomatic and supportive.

Therapeutic Uses of Zolac

What Zolac Treats: Main Uses and Benefits

Zolac is commonly used across conditions characterized by periods of heightened symptoms, applied across domains where additional symptomatic support is needed. Its use is considered relevant for easing symptoms associated with Major Depressive Disorder (MDD), Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD).

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as overwhelming fear, persistent sadness, and unwanted, repetitive thoughts. It supports management of these symptoms that interfere with daily comfort. In clinical settings that involve acute or unstable symptom patterns, Zolac is commonly used to help with comfort during periods of heightened symptoms and may assist with maintaining functional stability.

“It is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability during episodes of heightened discomfort.”

This supportive relief generally contributes to easing the overall symptom load, which is relevant for managing symptoms that interfere with daily comfort.


Quick Fact: Relief for Overwhelming Worry

It is commonly used when symptoms create noticeable physiological strain, and is relevant for easing acute manifestations of anxiety and panic.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zolac (Bromocriptine Mesilate)?

Eligibility for Zolac use is strictly defined by regulatory guidelines based on a patient's pre-existing health conditions and life stage. The medicine is primarily intended for adult patients with conditions related to hyperprolactinemia, such as prolactin-secreting pituitary adenomas. Use in adolescents 16 years of age and older is established for specific indications, but safety and effectiveness are not established for most uses in children younger than 16.


Absolute Contraindications

Use of Zolac is absolutely contraindicated in patients with:

  • Known hypersensitivity to bromocriptine or other ergot alkaloids.
  • Uncontrolled hypertension or hypertensive disorders of pregnancy (e.g., pre-eclampsia).
  • A history of severe cardiovascular conditions.
  • Nursing women, as the medicine inhibits lactation.

Condition-Based Restrictions

Caution is required for patients with hepatic impairment, as the body may eliminate the medicine more slowly. Additionally, use is generally not recommended for patients with severe psychotic disorders or those with a history of peptic ulceration, and treatment is typically discontinued upon confirmation of pregnancy unless necessary for managing pituitary tumors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zolac (fluoxetine) has officially documented interactions with several categories of medicines and products, which may impose restrictions on co-administration.

Contraindicated Combinations

The co-administration of Zolac is contraindicated (must not be combined) with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and methylene blue. A suitable washout period of at least 14 days must separate the use of an MAOI and Zolac. The use of Zolac is also contraindicated with Pimozide.

Significant Drug Interactions

  • Other Serotonergic Drugs: Concomitant use with other medicinal products that enhance serotonergic activity—such as Triptans, Tricyclic Antidepressants (TCAs), Fentanyl, Tramadol, and St. John's Wort—requires caution due to the potential risk of Serotonin Syndrome.
  • Agents Affecting Hemostasis: The risk of bleeding is increased when Zolac is combined with Warfarin, other oral Anticoagulants, NSAIDs (Nonsteroidal Anti-inflammatory Drugs), or other Antiplatelet agents. Close monitoring of INR/prothrombin time is required for patients on anticoagulants.
  • CYP2D6 Substrates: Zolac is a known inhibitor of the CYP2D6 enzyme. Co-administration with drugs primarily metabolized by this enzyme (e.g., flecainide, propafenone) may lead to increased plasma concentrations of the co-administered drug.

Mechanism of Action

Central Interruption of the Endocrine Command

Zolac acts as an agonist that specifically targets gonadotropin-releasing hormone (GnRH) receptors located on the pituitary gland cells. Continuous binding of the drug to these receptors leads to their rapid downregulation and subsequent desensitization, thereby interrupting the central signaling pathway that regulates the release of sex hormones.

Sustained Reduction of Circulating Sex Hormones

This central blockade prevents the pituitary gland from adequately releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The resulting absence of these stimulating signals causes the gonads (testicles or ovaries) to significantly reduce the synthesis and release of estrogen and testosterone. The physiological consequence is a profound and sustained reduction in the concentration of these circulating sex hormones throughout the body.

Modulating Hormone-Dependent Physiological States

The controlled reduction in sex hormones alters the internal physiological environment, resulting in a decreased influence of these steroid hormones on various target tissues and organs. This reflects the modulation of biological processes that are primarily driven by sex hormone signaling.

Dosage and Administration Information

How to Use Zolac

The administration of Zolac, which contains Bromocriptine Mesilate, follows specific parameters for route, dose, and timing based on the indication.

Administration Scope

Rule Official Instruction
Route of Administration The medicine is strictly for oral administration (by mouth).
Dosing Schedule Use involves a wide range of differentiated dosages. Starting doses are low, typically 0.8 mg to 2.5 mg daily. The required maintenance doses vary significantly, reaching up to 100 mg daily for Acromegaly or Parkinson’s Disease, but are limited to 4.8 mg for the quick-release formulation.
Timing in relation to meals All formulations must be taken with food to mitigate gastrointestinal effects.
Special procedural conditions The quick-release formulation (0.8 mg) must be administered once daily within two hours after waking in the morning. Initial doses for other indications are frequently taken at bedtime.
Age-group rules Specific initial and maximum daily doses are established for pediatric patients (7 - 17 years) for certain conditions.
Missed-dose rules For the quick-release formulation, a missed dose should be skipped entirely for that day, and the usual schedule resumed the following morning.

Instruction Classifications (High-Level)

The usage protocol is defined by oral administration, utilizing a once daily or multiple times per day frequency pattern based on the indication. Treatment involves gradual dose titration, where small increments (e.g., 1.25 mg) are applied over periods of 2 to 7 days until the required maintenance level is achieved.


Resulting Procedural Structure

Official use mandates that different tablet formulations are not interchangeable for their approved uses. The core protocol requires that all administration is synchronized with meal times and that the dose does not exceed the established maximum limit for the specific condition. This approach supports standardized and precise administration.

Recent Clinical Evidence

Zolac: Recent Clinical Evidence


Neuropathic Pain Studies

Research has explored whether this combination is associated with changes in quality of life and whether it may affect the total pain burden in individuals with chronic pain. Research evaluated whether the combination is associated with an onset of symptomatic change and duration of that change for chronic neuropathic pain.


Mobility and Function Studies

Studies observed data related to changes in symptoms often measured in conditions associated with inflammation and mobility measures. These findings from studies contribute to the body of evidence regarding treatment approaches following traditional single-agent therapies. The primary studies reported data related to physical function measures and provided preliminary findings regarding the treatment’s potential role in management strategies.


Safety and Tolerability Reports

Clinical reports summarized findings related to how adult study participants tolerated the treatment, and some studies suggest follow-up for signs of fatigue. The research protocol included advice for participants to avoid combining this treatment with other strong central nervous system depressants. While some studies reported mixed results, current research continues to examine the treatment’s role in managing chronic pain.

Key Studies & References Zolac Combination Therapy for Chronic Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Zolac (FAQ)


Q: Does Zolac cause weight gain or loss?

Official information mentions changes in appetite and weight as reported side effects. Specifically, regulatory documents have noted loss of appetite (anorexia) and weight loss as less common adverse reactions associated with the use of Zolac.

Q: Is Zolac known to interact with birth control pills?

For specific approved uses, the official guidance specifically recommends using a method of birth control other than hormonal contraceptives (pills, patches, or rings). This advice is typically given until normal menstrual periods have resumed.

Q: Is Zolac a kind of antidepressant?

No, official classification documents define Zolac as a Dopamine Agonist and a Prolactin Inhibitor. This means the medicine works by influencing specific receptors in the brain to regulate hormones and chemical signals. Its structural classification is a semisynthetic ergot alkaloid derivative.

Q: How long does it typically take for Zolac to start working?

The time it takes for Zolac to show an effect varies by the condition being treated. Studies show that for certain hormonal imbalances, a response may be seen within a few days. However, more significant physiological changes are described in studies as typically requiring 6 to 8 weeks for an initial effect to be observed.

Q: Can Zolac be taken with common pain relievers like ibuprofen?

Official warnings note that combining Zolac with nonsteroidal anti-inflammatory drugs (NSAIDs), which includes common pain relievers like ibuprofen, may lead to an increased risk of bleeding. If this combination is necessary, patients receiving blood-thinning medicines alongside Zolac require close monitoring as described in regulatory documents.

Q: What are the most common reasons a doctor might prescribe Zolac?

The approved uses for Zolac are defined by regulatory authorities. These include managing conditions related to high levels of the hormone prolactin (hyperprolactinemia), prolactin-secreting tumors in the pituitary gland, acromegaly, and managing the symptoms of Parkinson's disease. A quick-release formulation is also approved for Type 2 diabetes.

Q: Does Zolac affect sleep patterns?

Official safety information reports that Zolac may cause side effects related to the nervous system. These can include feelings of drowsiness, difficulty falling asleep or staying asleep (insomnia), and reports of nightmares.

Q: How long do people typically need to take Zolac?

The total duration of use varies widely and depends entirely on the specific health condition being managed. For some uses, the duration may be fixed (e.g., 14 days), while treatment for chronic conditions like prolactinomas and Parkinson's disease may require long-term use.

Q: Are there any long-term effects of taking Zolac?

For patients using Zolac in prolonged and high-dose daily regimens, regulatory warnings have noted risks of fibrotic changes. These include cardiac valvular fibrosis (thickening of heart valves) and pleural/retroperitoneal fibrosis, which are risks associated with the drug's class.

Q: Can Zolac make you feel anxious or restless?

Yes, official documents list adverse reactions affecting mental state and movement. These can include feelings of anxiety, nervousness, psychomotor agitation (a feeling of restlessness or excitement), and confusion.

Q: Is Zolac a controlled substance?

No, Zolac (Bromocriptine Mesilate) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies. It is categorized as a prescription-only medicine.

Q: Is it normal to experience vivid dreams while taking Zolac?

Nightmares and vivid dreams have been reported as less frequent side effects in official safety documents associated with the use of Zolac.

Q: What is the risk of developing dependence on Zolac?

Official sources do not classify it as a controlled substance, and studies have not established a clear risk of dependence.

Q: Can Zolac be used by older adults?

The therapeutic experience in the geriatric population (over 65 years of age) is limited. Official monographs indicate that closer monitoring may be necessary when this medicine is administered to older patients.

Q: How quickly do the side effects of Zolac usually start and stop?

Adverse effects, particularly nausea, dizziness, and low blood pressure, are most commonly reported when starting the therapy or after increasing a dose. Symptoms like the flu-like syndrome are most prominent early on and generally lessen with continued use of the medicine.

Q: Is Zolac typically taken once or multiple times a day?

The administration frequency depends on the specific condition it is treating. While the quick-release formulation is taken once daily in the morning for certain indications, treatment for other conditions may require the medicine to be taken multiple times per day in divided doses.

Q: How does the time of day I take Zolac influence its effect?

Timing is important for all formulations and is based on indication. For the quick-release tablets, taking the dose within two hours of waking is crucial for the intended effect related to circadian rhythm. For other uses, initial doses are frequently instructed to be taken at bedtime.

Q: Can men and women experience different side effects from Zolac?

Official warnings have noted a potentially higher risk of serious cardiovascular events, such as heart attack or stroke, in women who have recently given birth and take the medicine to stop milk production.

Q: Can Zolac be crushed or chewed if someone has trouble swallowing pills?

The suitability of crushing or chewing depends on the specific tablet formulation you are using. Official patient information often contains specific instructions regarding modifications like crushing or cutting tablets. Consulting this information is necessary because suitability depends on the specific product formulation.

Q: What conditions does Zolac treat, besides the main use?

In addition to conditions resulting from high prolactin levels (hyperprolactinemia), Zolac is officially indicated for the symptomatic management of Parkinson's disease, the hormone disorder acromegaly, and prolactin-dependent male hypogonadism.

Q: What happens if Zolac is taken in higher amounts than prescribed?

Taking higher amounts than prescribed is described in regulatory documents as potentially leading to symptoms such as nausea, vomiting, dizziness, excessive sleepiness, lightheadedness, and temporary visual or auditory hallucinations.

Q: Is it possible to be allergic to Zolac?

Yes, official safety documents state that Zolac is absolutely contraindicated (must not be used) in patients with a known hypersensitivity (a severe allergic reaction) to bromocriptine, other related medicines known as ergot alkaloids, or any other component in the formulation.

Q: Does Zolac interact with common over-the-counter cold medicines?

Caution is noted when Zolac is used with certain sympathomimetic agents, which are often found in over-the-counter cold and cough remedies (e.g., pseudoephedrine). Combining these medicines may increase the risk of adverse cardiovascular effects, such as elevated blood pressure and heart rate.

Q: What if I'm taking multiple medications; how can I check for Zolac interactions?

Official guidance emphasizes the need for patients to inform their healthcare team about all other medicines, vitamins, and herbal products they are using. This is a necessary step that allows the team to check for possible drug-drug interactions, and official resources are typically consulted to ensure safety.

How should Zolac be stored and disposed of?

Storage and Disposal Requirements for Zolac (Bromocriptine Mesilate)

Zolac tablets must be stored according to specific regulatory requirements to maintain product quality. The medication must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. It must be protected from light and moisture and should not be frozen. The tablets must remain in a tight, light-resistant container, preferably the original packaging, and kept out of the sight and reach of children.

Disposal of any unused or expired Zolac must be conducted in accordance with local regulations. The preferred method is to utilize an official drug take-back program. The medication should not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zolac found in:

A-Z Index: